Alendronate Sodium

Profiles of Drug Substances, Excipients and Related Methodology

Volumn 38, Issue , 2013, Pages 1-33

  Ananchenko, Gennady ^a   Novakovic, Jasmina ^a   Tikhomirova, Anna ^a  

^a Apotex Inc   (Canada)

Author keywords

ADME; Alendronate sodium; Bisphosphonates; Bone resorption; Chemical properties; Osteoporosis; Pharmacodynamics; Pharmacokinetics; Physical properties; Preparation

Indexed keywords

ALENDRONIC ACID;

ARTICLE; CAPILLARY ELECTROPHORESIS; CARBON NUCLEAR MAGNETIC RESONANCE; CRYSTALLOGRAPHY; DISSOCIATION CONSTANT; DRUG ADSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG IMPURITY; DRUG METABOLISM; DRUG NOMENCLATURE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; INFRARED SPECTROSCOPY; ION PAIR CHROMATOGRAPHY; IONIC STRENGTH; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MOLECULAR WEIGHT; NITROGEN NUCLEAR MAGNETIC RESONANCE; NONHUMAN; PARTITION COEFFICIENT; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; POTENTIOMETRIC TITRATION; POWDER X RAY DIFFRACTION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SOLID PHASE EXTRACTION; STEADY STATE; STOMACH ABSORPTION; TANDEM MASS SPECTROMETRY; THERMODYNAMICS; THIN LAYER CHROMATOGRAPHY; ULTRAVIOLET SPECTROSCOPY; URINARY EXCRETION; WETTABILITY; X RAY DIFFRACTION;

EID: 84878171504     PISSN: 18715125     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-407691-4.00001-0     Document Type: Chapter

References (88)

1. Russell R.G.G. Bisphosphonates: the first 40 years. Bone 2011, 49:2-19.
2. Hägele G., Szakács Z., Ollig J., Hermens S., Pfaff C. NMR-controlled titrations: characterizing aminophosphonates and related structures. Heteroatom Chem. 2000, 11:562-582.
3. Kabachnik M.I., Medved T.J., Djatlova N.M., Polikarpov J.M., Sherbakov B.K., Belskij F.I. Synthesis and acid-base and complexing properties of amino-substitutedα-hydroxyalkylidenediphosphonic acids. Bull. Acad. Sci USSR Div. Chem. Sci.. Izv. Akad. Nauk., Ser. Khim. 1978, 27:433-437. (Eng. Ed.) (Russian edition).
4. Dyba M., Kozlowski H., Tlalka A., Leroux Y., Manouni D.E. Oxovanadium(IV) complexes of 1-hydroxyalkane-1,1-diyldiphosphonic acids. Pol. J. Chem. 1998, 72:1148-1153.
5. Dyba M., Jezowska-Bojczuk M., Kiss E., Kiss T., Kozlowski H., Leroux Y., Manouni D.E. 1-Hydroxyalkane-1,1-diyldiphosphonates as potent chelating agents for metal ions. Potentiometric and spectroscopic studies of copper (II) coordination. J. Chem. Soc. Dalton Trans. 1996, 1119-1123.
6. Kubicek V., Kotek J., Hermann P., Lukes I. Aminoalkylbis(phosphonates): their complexation properties in solution and in the solid state. Eur. J. Inorg. Chem. 2007, 2007:333-344.
7. Boichenko A.P., Markov V.V., Kong H.L., Matveeva A.G., Loginova L.P. Re-evaluated data of dissociation constants of alendronic, pamidronic and olpadronic acids. Cent. Eur. J. Chem. 2009, 7:8-13.
8. Kamneva N.N., Boichenko A.P., Ivanov V.V., Markov V.V., Loginova L.P. Acid-base properties and complexation of alendronic acid in water-ethanol and ultramicroheterogenous micellar media of Brij 35. Ukr. Khim. Zh. 2012, 78:74-80.
9. Palazzo B., Iafisco M., Laforgia M., Margiotta N., Natile G., Bianchi C.L., Walsh D., Mann S., Roveri N. Biomimetic hydroxyapatite-drug nanocrystals as potential bone substitutes with antitumor drug delivery properties. Adv. Funct. Mater. 2007, 17:2180-2188.
10. Meloun M., Ferenčíková Z., Netolická L., Pekárek T. Thermodynamic dissociation constants of alendronate and ibandronate by regression analysis of potentiometric data. J. Chem. Eng. Data 2011, 56:3848-3854.
11. The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals, 14th ed., Merck & Co., Inc., Whitehouse Station, NJ, USA, monograph 229, 2006, p. 42.
12. Li J., Sun J., He Z. Quantitative structure-retention relationship studies with immobilized artificial membrane chromatography II: partial least squares regression. J. Chromatogr. A 2007, 1140:174-179.
13. Sanderson H., Thomsen M. Comparative analysis of pharmaceuticals versus industrial chemicals acute aquatic toxicity classification according to the United Nations classification system for chemicals. Assessment of the (Q)SAR predictability of pharmaceuticals acute aquatic toxicity and their predominant acute toxic mode-of-action. Toxicol. Lett. 2009, 187:84-93.
14. Vega D., Baggio R., Garland M.T. Monosodium 4-amino-1-hydroxy-1,1-butanediyldiphosphonate trihydrate (alendronate). Acta Cryst. 1996, C52:2198-2201.
15. Ohanessian J., Avenel D., Manouni D.E., Benramdane M. The molecular structure of 4-amino-1-hydroxy butylidene-1 bisphosphonic acid (AHBBPA); an uncommon anhydrous hydroxybisphosphonic acid. Phosphorus Sulfur Silicon Relat. Elem. 1997, 129:99-110.
16. Leroux Y., El Manouni D., Safsaf A., Neuman A., Gillier H. Etude structurale de l'acide butane hydroxy-1 amino-4 diphosphonique-1,1'. Phosphorus Sulfur Silicon Relat. Elem. 1991, 63:181-191.
17. Asnani M., Vyas K., Bhattacharya A., Devarakonda S., Chakraborty S., Mukherjee A.K. Ab initio structure determination of anhydrous sodium alendronate from laboratory powder X-ray diffraction data. J. Pharm. Sci. 2009, 98:2113-2121.
18. US2003/0065214 (2003), Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof.
19. US2005/0113343 (2005), Solid-state form of alendronate sodium and preparation thereof.
20. Kieczykowski G.R., Jobson R.B., Melillo D.G., Reinhold D.F., Grenda V.J., Shinkai I. Preparation of (4-amino-1-hydroxybutylidene)bisphosphonic acid sodium salt, MK-217 (alendronate sodium). An improved procedure for the preparation of 1-hydroxy-1,1-bisphosphonic acids. J. Org. Chem. 1995, 60:8310-8312.
21. http://riodb01.ibase.aist.go.jp/sdbs/cgi-bin/cre_frame_disp.cgi?spectrum_type=ir&sdbsno=52123.
22. Rubino M.T., Agamennone M., Campestre C., Campiglia P., Cremasco V., Faccio R., Laghezza A., Loiodice F., Maggi D., Panza E., Rossello A., Tortorella P. Biphenyl sulfonylamino methyl bisphosphonic acids as inhibitors of matrix metalloproteinases and bone resorption. ChemMedChem 2011, 6:1258-1268.
23. WO2005/047282 (2005), Antiresorptive mutual salt of raloxifene and biphosphonic acid 2005.
24. Grossmann G., Grossmann A., Ohms G., Breuer E., Chen R., Golomb G., Cohen H., Hägele G., Classen R. Solid-state NMR of bisphosphonates adsorbed on hydroxyapatite. Magn. Res. Chem. 2000, 38:11-16.
25. Ironside M.S., Duer M.J., Reid D.G., Byard S. Bisphosphonate protonation states, conformations, and dynamics on bone mineral probed by solid-state NMR without isotope enrichment. Eur. J. Pharm. Biopharm. 2010, 76:120-126.
26. Mao J., Mukherjee S., Zhang Y., Cao R., Sanders J.M., Song Y., Zhang Y., Meints G.A., Gao Y.G., Mukkamala D., Hudock M.P., Oldfield E. Solid-state NMR, crystallographic, and computational investigation of bisphosphonates and farnesyl diphosphate synthase-bisphosphonate complexes. J. Am. Chem. Soc. 2006, 128:14485-14497.
27. Mukherjee S., Song Y., Oldfield E. NMR investigations of the static and dynamic structures of bisphosphonates on human bone: a molecular model. J. Am. Chem. Soc. 2008, 130:1264-1273.
28. n in negative ion mode. Int. J. Mass Spectr. 2010, 295:85-93.
29. 2012 (accessed 20.08.12). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000619/WC500024249.pdf.
30. US4407761A, Process for the production of ω-amino-1-hydroxyalkylidene-1,1-bisphosphonic acid, 1983.
31. Srinivasa Rao D.V.N., Dandala R., Narayanan G.K.A.S.S., Lenin R., Sivakumaran M., Naidu A. Novel procedure for the synthesis of 1-hydroxy-1,1-bisphosphonic acids using phenols as medium. Synth. Commun. 2007, 37:4359-4365.
32. Mustafa D.A., Kashemirov B.A., McKenna C.E. Microwave-assisted synthesis of nitrogen-containing 1-hydroxymethylenebisphosphonate drugs. Tetrahedron Lett. 2011, 52:2285-2287.
33. Xu G., Xie Y., Wu X. A facile and direct synthesis of alendronate from pyrollidone. Org. Prep. Proc. Int. 2004, 36:185-187.
34. Mizrahi D.M., Waner T., Segall Y. α-Amino acid derived bisphosphonates. Synthesis and anti-resorptive activity. Phosphorus Sulfur Silicon Relat. Elem. 2001, 173:1-25.
35. Guénin E., Monteil M., Bouchemal N., Prangé T., Lecouvey M. Syntheses of phosphonic esters of alendronate, pamidronate and neridronate. Eur. J. Org. Chem. 2007, 2007:3380-3391.
36. Egorov M., Aoun S., Padrines M., Redini F., Heymann D., Lebreton J., Mathé-Allainmat M. A one-pot synthesis of 1-hydroxy-1,1-bis(phosphonic acid)s starting from the corresponding carboxylic acids. Eur. J. Org. Chem. 2011, 2011:7148-7154.
37. Sodium Alendronate, European Pharmacopoeia 7.0, Council of Europe, 2010, pp. 2908-2909.
38. Alendronic Acid Tablets, British Pharmacopoeia 2013, Medicines and Healthcare Products Regulatory Agency, vol. III, 2012, pp. 2487-2489.
39. Alendronate Sodium, U.S. Pharmacopeia-National Formularly, USP35/NF30, The United States Pharmacopoeial Convention, 2011, pp. 2093-2094.
40. Alendronate sodium Tablets, U.S. Pharmacopeia-National Formularly, USP35/NF30, The United States Pharmacopoeial Convention, 2011, pp. 2094-2096.
41. Zacharis C.K., Tzanavaras P.D. Determination of bisphosphonate active pharmaceutical ingredients in pharmaceuticals and biological material: a review of analytical methods. J. Pharm. Biomed. Anal. 2008, 48:483-496.
42. De Marco J.D., Biffar S.E., Reed D.G., Brooks M.A. The determination of 4-amino-1-hydroxybutane-1,1-diphosphonic acid monosodium salt trihydrate in pharmaceutical dosage forms by high-performance liquid chromatography. J. Pharm. Biomed. Anal. 1989, 7:1719-1727.
43. Samdancioglu S., Calis S., Kir S., Sumnu M. The determination of alendronate sodium in microparticular systems by high performance liquid chromatography. FABAD J. Pharm. Sci. 2003, 28:183-192.
44. Kwong E., Chiu A.M., McClintock S.A., Cotton M.L. HPLC analysis of an amino bisphosphonate in pharmaceutical formulations using postcolumn derivatization and fluorescence detection. J. Chromatogr. Sci. 1990, 28:563-566.
45. Tsai E.W., Ip D.P., Brooks M.A. Determination of alendronate in pharmaceutical dosage formulations by ion chromatography with conductivity detection. J. Chromatogr. 1992, 596:217-224.
46. Thompson R., Grinberg N., Perpall H., Bicker G., Tway P. Separation of organophosphonates by ion chromatography with indirect photometric detection. J. Liq. Chromatogr. 1994, 17:2511-2531.
47. Tsai E.W., Chamberlin S.D., Forsyth R.J., Bell C., Ip D.P., Brooks M.A. Determination of bisphosphonate drugs in pharmaceutical dosage formulations by ion chromatography with indirect UV detection. J. Pharmaceut. Biomed. Anal. 1994, 12:983-991.
48. Qin X.-Z., Tsai E.W., Sakuma T., Ip D.P. Pharmaceutical application of liquid chromatography-mass spectrometry: II.1 ion chromatography-ion spray mass spectrometric characterization of Alendronate. J. Chromatogr. A 1994, 686:205-212.
49. Han Y.-H.R., Qin X.-Z. Determination of alendronate sodium by ion chromatography with refractive index detection. J. Chromatogr. A 1996, 719:345-352.
50. Lovdahl M.J., Pietrzyk D.J. Anion-exchange separation and determination of bisphosphonates and related analytes by post-column indirect fluorescence detection. J. Chromatogr. A 1999, 850:143-152.
51. Kovacevic M., Gartner A., Novic M. Determination of bisphosphonates by ion chromatography-inductively coupled plasma mass spectrometry. J. Chromatogr. A 2004, 1039:77-82.
52. Al Deeb S.K., Hamdan I.I., Al Najjar S.M. Spectroscopic and HPLC methods for the determination of alendronate in tablets and urine. Talanta 2004, 64:695-702.
53. Xie Z., Jiang Y., Zhang D.Q. Simple analysis of four bisphosphonates simultaneously by reverse phase liquid chromatography using n-amylamine as volatile ion-pairing agent. J. Chromatogr. A 2006, 1104:173-178.
54. Fernandes C., Leite R.S., Lanças F.M. Rapid determination of bisphosphonates by ion chromatography with indirect UV detection. J. Chromatogr. Sci. 2007, 45:236-241.
55. Abd El-Sattar O.I., Ahmad A.A., ElKady T. Validated and stability indicating HPLC-method for determination of alendronate sodium using phthaldialdehyde as a pre-column derivatizing agent. Egypt. J. Biomed. Sci. 2003, 11:35-45.
56. Pérez-Ruiz T., Martínez-Lozano C., García-Martínez M.D. A sensitive post-column photochemical derivatization/fluorimetric detection system for HPLC determination of bisphosphonates. J. Chromatogr. A 2009, 1216:1312-1318.
57. Warnke M.M., Breitbach Z.S., Dodbiba E., Crank J.A., Payagala T., Sharma P., Wanigasekara E., Zhang X., Armstrong D.W. Positive mode electrospray ionization mass spectrometry of bisphosphonates using dicationic and tricationic ion-pairing agents. Anal. Chim. Acta 2009, 633:232-237.
58. Kuljanin J., Janković I., Nedeljković J., Prstojević D., Marinković V. Spectrophotometric determination of alendronate in pharmaceutical formulations via complex formation with Fe(III) ions. J. Pharm. Biomed. Anal. 2002, 28:1215-1220.
59. Taha E.A., Youssef N.F. Spectrophotometric determination of some drugs for osteoporosis. Chem. Pharm. Bull. 2003, 51:1444-1447.
60. Tzanavaras P.D., Zacharis C.K., Theodoridis G.A., Kalaitzantonakis E.A., Voulgaropoulos A.N. Normal spectrophotometric and stopped-flow spectrofluorimetric sequential injection methods for the determination of alendronic acid, an anti-osteoporosis amino-bisphosphonate drug, in pharmaceuticals. Anal. Chim. Acta 2005, 547:98-103.
61. Koba M., Koba K., Przyborowski L. Application of UV-derivative spectrophotometry for determination of some bisphosphonates drugs in pharmaceutical formulations. Acta Pol. Pharm. 2008, 65:289-294.
62. Walash M.I., Metwally M.E., Eid M., El-Shaheny R.N. Validated spectrophotometric methods for determination of Alendronate sodium in tablets through nucleophilic aromatic substitution reactions. Chem. Cent. J. 2012, 6:25-40.
63. Ulbrich W., Lamprecht A. Fluorimetric quantification of clodronate and Alendronate in aqueous samples and in serum. Talanta 2011, 84:437-442.
64. Reed D.G., Martin G.P., Konieczny J.M., Brooks M.A. The determination of alendronate sodium in tablets by inductively coupled plasma (ICP). J. Pharm. Biomed. Anal. 1995, 13:1055-1058.
65. Tsai E.W., Singh M.M., Lu H.H., Ip D.P., Brooks M.A. Application of capillary electrophoresis to pharmaceutical analysis. Determination of alendronate in dosage forms. J. Chromatogr. A 1992, 626:245-250.
66. Bexheti D., Anderson E.I., Hutt A.J., Hanna-Brown M. Evaluation of multidimensional capillary electrophoretic methodologies for determination of amino bisphosphonate pharmaceuticals. J. Chromatogr. A 2006, 1130:137-144.
67. Razak O.A., Belal S.F., Bedair M.M., Haggag R.S. The utilization of copper(II) phosphate for the anodic stripping voltammetric assay of alendronate sodium, desferrioxamine mesylate and lisinopril. Talanta 2003, 59:1061-1069.
68. de Haro Moreno A., Pezza H.R., Pezza L. Potentiometric determination of Alendronate in pharmaceutical formulations. Chem. Anal. (Warsaw) 2004, 49:351-358.
69. Svidritskii P., Jiang M.S., Il'in V.I., Dyn'kov D.I., Pirogov A.V., Shpigun O.A. The determination of alendronate ion and certain inorganic ions using capillary electrophoresis. Moscow Univ. Chem. Bull. (Eng. Ed.) 2010, 65:42-48. Vestnik Moskovskogo Universiteta, Seriya 2: Khimiya, 51, 53-61 (Russian Edition).
70. Zhu L.S., Lapko V.N., Leey J.W., Basir Y.J., Kafonek C., Olsen R., Briscoe C. A general approach for the quantitative analysis of bisphosphonates in human serum and urine by high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2006, 20:3421-3426.
71. Su S.-W., Liao Y.-C., Whang C.-W. Analysis of alendronate in human urine and plasma by magnetic solid-phase extraction and capillary electrophoresis with fluorescence detection. J. Sep. Sci. 2012, 35:681-687.
72. Sparidans R.W., den Hartigh J. Chromatographic analysis of bisphorphonates. Pharm. World Sci. 1999, 21:1-10.
73. Ban E., Park J.-Y., Kim H.T., Kim C.-K. Determination of alendronate in low volumes of plasma by column-switching high-performance liquid chromatography method and its application to pharmacokinetic studies in human plasma. Arch. Pharm. Res. 2011, 34:2079-2086.
74. Chen M., Liu K., Zhong D., Chen X. Trimethylsilyldiazomethane derivatization coupled with solid-phase extraction for the determination of alendronate in human plasma by LC-MS/MS. Anal. Bioanal. Chem. 2012, 402:791-798.
75. Kline W.F., Matuszewski B.K., Bayne W.F. Determination of 4-amino-1-hydroxybutane-1,1-bisphosphonic acid in urine by automated pre-column derivatization with 2,3-naphthalenedicarboxyaldehyde and high-performance liquid chromatography with fluorescence detection. J. Chromatogr. 1990, 534:139-149.
76. Kline W.F., Matuszewski B.K. Improved determination of the bisphosphonate alendronate in human plasma and urine by automated precolumn derivatization and high-performance liquid chromatography with fluorescence and electrochemical detection. J. Chromatogr. 1992, 583:183-193.
77. Ptáček P., Kli{dotless}ma J., Macek J. Determination of alendronate in human urine as 9-fluorenylmethyl derivative by high-performance liquid chromatography. J. Chromatogr. B 2002, 767:111-116.
78. Yun M.-H., Kwon K. High-performance liquid chromatography method for determining alendronate sodium in human plasma by detecting fluorescence: application to a pharmacokinetic study in humans. J. Pharm. Biomed. Anal. 2006, 40:168-172.
79. Apostolou C., Dotsikas Y., Kousoulos C., Tsatsou G., Colocouri F., Soumelas G.-S., Loukas Y.L. Application of a semi-automated 96-well format solid-phase extraction, column-switching, fluorescence detection protocol for the determination of alendronate in human urine samples obtained from a bioequivalence study. J. Pharm. Biomed. Anal. 2007, 43:1151-1155.
80. Tarcomnicu I., Silvestro L., Savu S.R., Gherase A., Dulea C. Development and application of a high-performance liquid chromatography-mass spectrometry method to determine alendronate in human urine. J. Chromatogr. A 2007, 1160:21-33.
81. Porras A.G., Holland S.D., Gertz B.J. Pharmacokinetics of alendronate. Clin. Pharmacokinet. 1999, 36:315-328.
82. Lin J.H., Chen I.-W., Deluna F.A. On the absorption of alendronate in rats. J. Pharm. Sci. 1994, 83:1741-1746.
83. Gertz B.J., Holland S.D., Kline W.F., Matuszewski B.K., Porras A.G. Clinical pharmacology of alendronate sodium. Osteoporos. Int. 1993, 3(Suppl. 3):S13-S16.
84. Gertz B.J., Holland S.D., Kline W.F., Matuszewski B.K., Freeman A., Quan H., Lasseter K.C., Mucklow J.C., Porras A.G. Studies of the oral bioavailability of alendronate. Clin. Pharm. Ther. 1995, 58:288-298.
85. Lin J.H. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996, 18:75-85.
86. Lin H., Chen I.W., deLuna F.A., Hichens M. Role of calcium in plasma protein binding and renal handling of alendronate in hypo- and hypercalcemic rats. J. Pharmacol. Exp. Ther. 1993, 267:670-675.
87. Lin H., Chen I.W., Duggan D.E. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab. Dispos. 1992, 20:473-478.
88. Cocquyt V., Kline W.F., Gertz B.J., Van Belle S.J., Holland S.D., DeSmet M., Quan H., Vyas K.P., Zhang K.E., De Grève J., Porras A.G. Pharmacokinetics of intravenous alendronate. J. Clin. Pharmacol. 1999, 39:385-393.